23andme Holding CO 8-K filings

The U.S. Bankruptcy Court has confirmed Chrome Holding Co.'s Chapter 11 plan, leading to the cancellation of all outstanding common stock and the establishment of a Plan Administration Trust for creditor distributions.

Chrome Holding Co. has filed its Third Amended Joint Plan under Chapter 11, outlining asset sales and settlement agreements for data breach claims, with a confirmation hearing set for November 19, 2025.

Chrome Holding Co. (formerly 23andMe Holding Co.) filed its September 2025 monthly operating report, detailing financial status and ongoing Chapter 11 proceedings, including asset sales and plan confirmation efforts.

Chrome Holding Co. (formerly 23andMe Holding Co.) filed its August 2025 monthly operating report, detailing financial activities and ongoing Chapter 11 proceedings, including asset sales and a significant net loss.

Chrome Holding Co. (formerly 23andMe Holding Co.) has filed its Second Amended Joint Plan of Reorganization and Disclosure Statement in its Chapter 11 bankruptcy proceedings, detailing asset sales and settlement of massive data breach claims.

Chrome Holding Co. (formerly 23andMe Holding Co.) filed monthly operating reports detailing its Chapter 11 bankruptcy progress, including a significant asset sale and a return to positive equity.

Chrome Holding Co., currently undergoing Chapter 11 bankruptcy, has entered into a definitive agreement to sell its Lemonaid telehealth business to Bambumeta Ventures for $10 million in cash.

Chrome Holding Co. announces its CEO, Joseph Selsavage, will serve dual roles and receive adjusted compensation during the Chapter 11 transition period.

Chrome Holding Co. and its subsidiaries filed a joint Chapter 11 plan to wind down operations and distribute assets, following the sale of most assets for $302.5 million and ongoing data breach settlements.

23andMe Holding Co. has officially changed its corporate name to Chrome Holding Co., effective August 14, 2025.

23andMe Holding Co. has completed the sale of substantially all of its assets, including its Personal Genome Service and Research Services business lines, to TTAM Research Institute, an affiliate of co-founder Anne Wojcicki, for $305 million in cash, while remaining in Chapter 11 bankruptcy.

23andMe Holding Co. has received U.S. Bankruptcy Court approval for the sale of substantially all of its assets to TTAM Research Institute, a nonprofit led by co-founder Anne Wojcicki, for $305 million in cash, marking a significant step in its Chapter 11 reorganization.

23andMe Holding Co. has agreed to sell substantially all of its assets, including its Personal Genome Service and Research Services, to TTAM Research Institute, a nonprofit led by co-founder Anne Wojcicki, for $305 million in cash, following a competitive bidding process during its Chapter 11 bankruptcy.

23andMe has entered into an agreement to be acquired by Regeneron Pharmaceuticals for $256 million, pending court approval, as part of its Chapter 11 bankruptcy proceedings.

23andMe Holding Co. obtains a $35 million debtor-in-possession financing facility from JMB Capital Partners Lending, LLC to support its operations during Chapter 11 proceedings.

23andMe Holding Co. is set to be delisted from the Nasdaq Stock Market after filing for Chapter 11 bankruptcy.

23andMe has voluntarily filed for Chapter 11 bankruptcy to facilitate a sale process aimed at maximizing stakeholder value, while also announcing leadership changes and securing $35 million in DIP financing.

23andMe's Q3 FY2025 results show increased revenue due to a one-time research payment, but the company faces significant liquidity challenges and has implemented major cost-cutting measures.

23andMe announced a 21% improvement in GAAP net loss and a 26% improvement in adjusted EBITDA for the second quarter of fiscal year 2025, alongside new product launches and strategic restructuring.

23andMe has regained compliance with Nasdaq's minimum bid price and corporate governance requirements, allowing its stock to continue trading on the Nasdaq Capital Market.

23andMe has appointed three new independent directors to its board, effective October 28, 2024, to enhance its corporate governance and strategic direction.

23andMe has completed a 1-for-20 reverse stock split of its Class A and Class B common stock, effective October 16, 2024, to increase its share price and potentially attract a broader range of investors.

23andMe Holding Co. received a deficiency letter from Nasdaq due to non-compliance with corporate governance requirements following recent director resignations.

Seven independent directors of 23andMe's board have resigned, citing strategic disagreements with CEO Anne Wojcicki and her concentrated voting power.

23andMe Holding Co. held its 2024 Annual Meeting of Stockholders, where shareholders voted on key proposals including the election of directors, executive compensation, a reverse stock split, and the ratification of the company's auditor.

23andMe's first quarter fiscal 2025 results show a 34% revenue decrease year-over-year, alongside a restructuring of its therapeutics division and the resignation of a key executive.

23andMe's Special Committee has rejected CEO Anne Wojcicki's preliminary take-private proposal due to insufficient terms and lack of committed financing, and is exploring other options.

23andMe's CEO, Anne Wojcicki, has made a preliminary non-binding proposal to take the company private at $0.40 per share.

23andMe is focusing on expanding its recurring revenue streams, advancing its therapeutic pipeline, and leveraging its genetic database through AI and strategic partnerships.

23andMe's experimental cancer drug, 23ME-00610, shows promising early results in Phase 2 trials, including a confirmed partial response in a patient with pancreatic neuroendocrine cancer.